Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

zensei pharmaceutical industries co., ltd. - nitrendipine - pale yellow tablet, diameter: 6.2 mm, thickness: 3.3 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

zensei pharmaceutical industries co., ltd. - nitrendipine - pale yellow tablet, diameter: 6.2 mm, thickness: 3.2 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - nitrendipine - pale yellow tablet, diameter: 6.1 mm, thickness: 3.2 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - nitrendipine - pale yellowish white tablet, diameter: 6.1 mm, thickness: 3.2 mm

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - carvedilol, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; magnesium stearate; colloidal anhydrous silica; povidone; crospovidone - dilatrend is indicated for the treatment for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to moderate (nyha class ii & iii) congestive heart failure, as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators). indications as at 24 january 2002: dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators). indications as at 3 march 2003: dilatrend is indicated for the treatment of hypertension. data have not been provided to support t

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; magnesium stearate; colloidal anhydrous silica; povidone; crospovidone; iron oxide yellow; iron oxide red - dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to moderate (nyha class ii & iii) congestive heart failure, as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators). indications as at 24 january 2002: dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators). indications as at 3 march 2003: dilatrend is indicated for the treatment of hypertension. data have not been provided to support the use of this dru

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; magnesium stearate; colloidal anhydrous silica; povidone; crospovidone; iron oxide yellow - dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to moderate (nyha class ii & iii) congestive heart failure, as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators). indications as at 24 january 2002: dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators). indications as at 3 march 2003: dilatrend is indicated for the treatment of hypertension. data have not been provided to support the use of this dru

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - cefazolin sodium - powder for solution for injection/infusion - cefazolin sodium 1 g - antibacterials for systemic use

Egypt - English - EDA (Egyptian Drug Authority)

trend pharm - capsule - 100 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

desitin pharma ltd - levetiracetam - oral granules - 250mg